{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:33:05Z","timestamp":1792895585775,"version":"4.5.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1471-2407-14-915","type":"journal-article","created":{"date-parts":[[2014,12,4]],"date-time":"2014-12-04T05:05:08Z","timestamp":1417669508000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Case series discussion of cardiac and vascular events following carfilzomib treatment: possible mechanism, screening, and monitoring"],"prefix":"10.1186","volume":"14","author":[{"given":"Ajai","family":"Chari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daher","family":"Hajje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,12,4]]},"reference":[{"issue":"5","key":"5091_CR1","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV: Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014, 28 (5): 1122-1129. 10.1038\/leu.2013.313.","journal-title":"Leukemia"},{"issue":"14","key":"5091_CR2","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, Trudel S, Kukreti V, Bahlis N, Alsina M, Chanan-Khan A, Buadi F, Reu FJ, Somlo G, Zonder J, Song K, Stewart AK, Stadtmauer E, Kunkel L, Wear S, Wong AF, Orlowski RZ, Jagannath S: A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012, 120 (14): 2817-2825. 10.1182\/blood-2012-05-425934.","journal-title":"Blood"},{"key":"5091_CR3","unstructured":"Onyx Pharmaceuticals, Inc: Kyprolis (carfilzomib) package insert. http:\/\/www.kyprolis.com\/prescribing-information ,"},{"issue":"11","key":"5091_CR4","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","volume":"98","author":"D Siegel","year":"2013","unstructured":"Siegel D, Martin T, Nooka A, Harvey RD, Vij R, Niesvizky R, Badros AZ, Jagannath S, McCulloch L, Rajangam K, Lonial S: Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies. Haematologica. 2013, 98 (11): 1753-1761. 10.3324\/haematol.2013.089334.","journal-title":"Haematologica"},{"issue":"11","key":"5091_CR5","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1016\/S1074-5521(99)80128-8","volume":"6","author":"M Elofsson","year":"1999","unstructured":"Elofsson M, Splittgerber U, Myung J, Mohan R, Crews CM: Towards subunit-specific proteasome inhibitors: synthesis and evaluation of peptide \u03b1\u2032, \u03b2\u2032-epoxyketones. Chem Biol. 1999, 6 (11): 811-822. 10.1016\/S1074-5521(99)80128-8.","journal-title":"Chem Biol"},{"issue":"4","key":"5091_CR6","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1615\/CritRevImmunol.v21.i4.30","volume":"21","author":"M Groettrup","year":"2001","unstructured":"Groettrup M, van den Broek M, Schwarz K, Macagno A, Khan S, de Giuli R, Schmidtke G: Structural plasticity of the proteasome and its function in antigen processing. Crit Rev Immunol. 2001, 21 (4): 339-358.","journal-title":"Crit Rev Immunol"},{"issue":"3","key":"5091_CR7","doi-asserted-by":"publisher","first-page":"6383","DOI":"10.1158\/0008-5472.CAN-06-4086","volume":"67","author":"SD Demo","year":"2007","unstructured":"Demo SD, Kirk CJ, Aujay MA, Buchholz TJ, Dajee M, Ho MN, Jiang J, Laidig GJ, Lewis ER, Parlati F, Shenk KD, Smyth MS, Sun CM, Vallone MK, Woo TM, Molineaux CJ, Bennett MK: Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. Cancer Res. 2007, 67 (3): 6383-6391.","journal-title":"Cancer Res"},{"issue":"22","key":"5091_CR8","doi-asserted-by":"publisher","first-page":"7085","DOI":"10.1158\/1078-0432.CCR-09-0822","volume":"15","author":"OA O'Connor","year":"2009","unstructured":"O'Connor OA, Stewart AK, Vallone M, Molineaux CJ, Kunkel LA, Gerecitano JF, Orlowski RZ: A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res. 2009, 15 (22): 7085-7091. 10.1158\/1078-0432.CCR-09-0822.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"5091_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1124\/dmd.112.047662","volume":"41","author":"Z Wang","year":"2013","unstructured":"Wang Z, Yang J, Kirk C, Fang Y, Alsina M, Badros A, Papadopoulos K, Wong A, Woo T, Bomba D, Li J, Infante JR: Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib. Drug Metab Dispos. 2013, 41 (1): 230-237. 10.1124\/dmd.112.047662.","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"5091_CR10","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1038\/leu.2013.29","volume":"27","author":"AZ Badros","year":"2013","unstructured":"Badros AZ, Vij R, Martin T, Zonder JA, Kunkel L, Wang Z, Lee S, Wong AF, Niesvizky R: Carfilzomib in multiple myeloma patients with renal impairment: pharmacokinetics and safety. Leukemia. 2013, 27 (8): 1707-1714. 10.1038\/leu.2013.29.","journal-title":"Leukemia"},{"issue":"17","key":"5091_CR11","doi-asserted-by":"publisher","first-page":"4830","DOI":"10.1158\/1078-0432.CCR-11-3007","volume":"18","author":"M Alsina","year":"2012","unstructured":"Alsina M, Trudel S, Firman RR, Rosen PJ, O\u2019Connor OA, Comenzo RL, Wong A, Kunkel LA, Molineaux CJ, Goy A: A phase I single-agent study of twice-weekly consecutive-day dosing of the proteasome inhibitor carfilzomib in patients with relapsed or refractory multiple myeloma or lymphoma. Clin Cancer Res. 2012, 18 (17): 4830-4840. 10.1158\/1078-0432.CCR-11-3007.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"5091_CR12","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.clml.2012.08.003","volume":"12","author":"S Jagannath","year":"2012","unstructured":"Jagannath S, Vij R, Stewart AK, Trudel S, Jakubowiak AJ, Reiman T, Somlo G, Bahlis N, Lonial S, Kunkel LA, Wong A, Orlowski RZ, Siegel DS: An open-label single-arm pilot phase II study (PX-171-003-A0) of low-dose, single-agent carfilzomib in patients with relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2012, 12 (5): 310-318. 10.1016\/j.clml.2012.08.003.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"24","key":"5091_CR13","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"R Vij","year":"2012","unstructured":"Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V, Jagannath S, McDonagh KT, Alsina M, Bahlis NJ, Reu FJ, Gabrail NY, Belch A, Matous JV, Lee P, Rosen P, Sebag M, Vesole DH, Kunkel LA, Wear SM, Wong AF, Orlowski RZ, Siegel DS: An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood. 2012, 119 (24): 5661-5670. 10.1182\/blood-2012-03-414359.","journal-title":"Blood"},{"issue":"10","key":"5091_CR14","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1124\/dmd.111.039164","volume":"39","author":"J Yang","year":"2011","unstructured":"Yang J, Wang Z, Fang Y, Jiang J, Zhao F, Wong H, Bennett MK, Molineaux CJ, Kirk CJ: Pharmacokinetics, pharmacodynamics, metabolism, distribution, and excretion of carfilzomib in rats. Drug Metab Dispos. 2011, 39 (10): 1873-1882. 10.1124\/dmd.111.039164.","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"5091_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","volume":"12","author":"P Moreau","year":"2011","unstructured":"Moreau P, Pylypenko H, Grosicki S, Karamanesht I, Leleu X, Grishunina M, Rekhtman G, Masliak Z, Robak T, Shubina A, Arnulf B, Kropff M, Cavet J, Esseltine DL, Feng H, Girgis S, van de Velde H, Deraedt W, Harousseau JL: Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study. Lancet Oncol. 2011, 12 (5): 431-440. 10.1016\/S1470-2045(11)70081-X.","journal-title":"Lancet Oncol"},{"key":"5091_CR16","volume-title":"J Clin Oncol","author":"KP Papadopoulos","year":"2014","unstructured":"Papadopoulos KP, Siegel DS, Vesole DH, Lee P, Rosen ST, Zojwalla N, Holahan JR, Lee S, Wang Z, Badros A: Phase I study of 30-minute infusion of carfilzomib as single agent or in combination with low-dose dexamethasone in patients with relapsed and\/or refractory multiple myeloma. J Clin Oncol. 2014, doi:10.1200\/JCO.2013.52.3522"},{"issue":"Suppl 21","key":"5091_CR17","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1182\/blood.V120.21.947.947","volume":"120","author":"N Lendvai","year":"2012","unstructured":"Lendvai N, Landau H, Lesokhin A, Tsakos I, Koehne G, Chung D, Devlin S, Hassoun H, Giralt SA: Phase II study of infusional carfilzomib in patients with relapsed or refractory multiple myeloma. Blood. 2012, 120 (Suppl 21): 947-abstr","journal-title":"Blood"},{"issue":"23","key":"5091_CR18","doi-asserted-by":"publisher","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","volume":"120","author":"SH Armenian","year":"2012","unstructured":"Armenian SH, Sun CL, Vase T, Ness KK, Blum E, Francisco L, Venkataraman K, Samoa R, Wong FL, Forman SJ, Bhatia S: Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. Blood. 2012, 120 (23): 4505-4512. 10.1182\/blood-2012-06-437178.","journal-title":"Blood"},{"issue":"Supp 21","key":"5091_CR19","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1182\/blood.V120.21.2916.2916","volume":"120","author":"KD Kistler","year":"2012","unstructured":"Kistler KD, Rajangam K, Faich G, Lanes S: Cardiac event rates in patients with newly diagnosed and relapsed multiple myeloma in US clinical practice. Blood. 2012, 120 (Supp 21): 2916-abstr","journal-title":"Blood"},{"issue":"15s","key":"5091_CR20","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.1200\/jco.2013.31.15_suppl.8595","volume":"31","author":"S Atrash","year":"2013","unstructured":"Atrash S, Tullos A, Panozzo S, Waheed S, Van Rhee F, Restrepo A, Muzaffar J, Bakhous A, Grazziutti M, Shahid Z, Apewokin S, Abdallah AOA, Barlogie B, Usmani SZ: Retrospective analysis of cardiovascular (CV) events following compassionate use of carfilzomib (CFZ) in patients (Pts) with relapsed and refractory multiple myeloma (RRMM). J Clin Oncol. 2013, 31 (15s): 8595-abstr","journal-title":"J Clin Oncol"},{"issue":"6","key":"5091_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1182\/blood-2012-10-459883","volume":"121","author":"KM Kortuem","year":"2013","unstructured":"Kortuem KM, Stewart AK: Carfilzomib. Blood. 2013, 121 (6): 893-897. 10.1182\/blood-2012-10-459883.","journal-title":"Blood"},{"issue":"5789","key":"5091_CR22","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1038\/288373a0","volume":"288","author":"RF Furchgott","year":"1980","unstructured":"Furchgott RF, Zawadzki J: The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature. 1980, 288 (5789): 373-376. 10.1038\/288373a0.","journal-title":"Nature"},{"issue":"8","key":"5091_CR23","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.1097\/01.ASN.0000132474.50966.DA","volume":"15","author":"DH Endemann","year":"2004","unstructured":"Endemann DH, Schiffrin E: Endothelial dysfunction. J Am Soc Nephrol. 2004, 15 (8): 1983-1992. 10.1097\/01.ASN.0000132474.50966.DA.","journal-title":"J Am Soc Nephrol"},{"issue":"6","key":"5091_CR24","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1096\/fj.03-0724rev","volume":"18","author":"S Fogli","year":"2004","unstructured":"Fogli S, Nieri P, Breschi MC: The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004, 18 (6): 664-675. 10.1096\/fj.03-0724rev.","journal-title":"FASEB J"},{"issue":"2","key":"5091_CR25","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1093\/cvr\/cvp315","volume":"85","author":"K Stangl","year":"2010","unstructured":"Stangl K, Stangl V: The ubiquitin-proteasome pathway and endothelial (dys)function. Cardiovasc Res. 2010, 85 (2): 281-290. 10.1093\/cvr\/cvp315.","journal-title":"Cardiovasc Res"},{"issue":"23","key":"5091_CR26","doi-asserted-by":"publisher","first-page":"17407","DOI":"10.1074\/jbc.M000155200","volume":"275","author":"AT Bender","year":"2000","unstructured":"Bender AT, Demady DR, Osawa Y: Ubiquitination of neuronal nitric-oxide synthase in vitro and in vivo. J Biol Chem. 2000, 275 (23): 17407-17411. 10.1074\/jbc.M000155200.","journal-title":"J Biol Chem"},{"issue":"4","key":"5091_CR27","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1093\/oxfordjournals.jbchem.a003139","volume":"131","author":"H Ito","year":"2002","unstructured":"Ito H, Kamei K, Iwamoto I, Inaguma Y, Garcia-Mata R, Sztul E, Kato K: Inhibition of proteasomes induces accumulation, phosphorylation, and recruitment of HSP27 and \u03b1B-crystallin to aggresomes. J Biochem. 2002, 131 (4): 593-603. 10.1093\/oxfordjournals.jbchem.a003139.","journal-title":"J Biochem"},{"issue":"31","key":"5091_CR28","doi-asserted-by":"publisher","first-page":"21652","DOI":"10.1074\/jbc.M602105200","volume":"281","author":"Q Wei","year":"2006","unstructured":"Wei Q, Xia Y: Proteasome inhibition down-regulates endothelial nitric-oxide synthase phosphorylation and function. J Biol Chem. 2006, 281 (31): 21652-21659. 10.1074\/jbc.M602105200.","journal-title":"J Biol Chem"},{"issue":"2","key":"5091_CR29","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/med.20111","volume":"28","author":"S Meiners","year":"2008","unstructured":"Meiners S, Ludwig A, Stangl V, Stangl K: Proteasome inhibitors: poisons and remedies. Med Res Rev. 2008, 28 (2): 309-327. 10.1002\/med.20111.","journal-title":"Med Res Rev"},{"issue":"12","key":"5091_CR30","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.1016\/j.freeradbiomed.2006.03.003","volume":"40","author":"S Meiners","year":"2006","unstructured":"Meiners S, Ludwig A, Lorenz M, Dreger H, Baumann G, Stangl V, Stangl K: Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radic Biol Med. 2006, 40 (12): 2232-2241. 10.1016\/j.freeradbiomed.2006.03.003.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"5091_CR31","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1096\/fj.03-0054com","volume":"18","author":"V Stangl","year":"2004","unstructured":"Stangl V, Lorenz M, Meiners S, Ludwig A, Bartsch C, Moobed M, Vietzke A, Kinkel HT, Baumann G, Stangl K: Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin\u2013proteasome pathway. FASEB J. 2004, 18 (2): 272-279. 10.1096\/fj.03-0054com.","journal-title":"FASEB J"},{"issue":"9","key":"5091_CR32","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1161\/CIRCRESAHA.107.152959","volume":"101","author":"J Herrmann","year":"2007","unstructured":"Herrmann J, Saguner AM, Versari D, Peterson TE, Chade A, Olson M, Lerman LO, Lerman A: Chronic proteasome inhibition contributes to coronary atherosclerosis. Circ Res. 2007, 101 (9): 865-874. 10.1161\/CIRCRESAHA.107.152959.","journal-title":"Circ Res"},{"issue":"6","key":"5091_CR33","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1093\/eurjhf\/hft034","volume":"15","author":"J Herrmann","year":"2013","unstructured":"Herrmann J, Wohlert C, Saguner AM, Flores A, Nesbitt LL, Chade A, Lerman LO, Lerman A: Primary proteasome inhibition results in cardiac dysfunction. Eur J Heart Fail. 2013, 15 (6): 614-623. 10.1093\/eurjhf\/hft034.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"5091_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s12012-011-9146-7","volume":"12","author":"A Gupta","year":"2012","unstructured":"Gupta A, Pandey A, Sethi S: Bortezomib-induced congestive cardiac failure in a patient with multiple myeloma. Cardiovasc Toxicol. 2012, 12 (2): 184-187. 10.1007\/s12012-011-9146-7.","journal-title":"Cardiovasc Toxicol"},{"issue":"3","key":"5091_CR35","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/fcp.12039","volume":"28","author":"B Honton","year":"2014","unstructured":"Honton B, Despas F, Dumonteil N, Rouvellat C, Roussel M, Carrie D, Galinier M, Montastruc JL, Pathak A: Bortezomib and heart failure: case-report and review of the French Pharmacovigilance database. Fundam Clin Pharmacol. 2014, 28 (3): 349-352. 10.1111\/fcp.12039.","journal-title":"Fundam Clin Pharmacol"},{"key":"5091_CR36","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1186\/1471-2407-6-129","volume":"6","author":"J Voortman","year":"2006","unstructured":"Voortman J, Giaccone G: Severe reversible cardiac failure after bortezomib treatment combined with chemotherapy in a non-small cell lung cancer patient: a case report. BMC Cancer. 2006, 6: 129-10.1186\/1471-2407-6-129.","journal-title":"BMC Cancer"},{"issue":"3","key":"5091_CR37","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/j.1365-2141.2007.06659.x","volume":"138","author":"O Enrico","year":"2007","unstructured":"Enrico O, Gabriele B, Nadia C, Sara G, Daniele V, Giulia C, Antonio S, Mario P: Unexpected cardiotoxicity in haematological bortezomib treated patients. Br J Haematol. 2007, 138 (3): 396-397. 10.1111\/j.1365-2141.2007.06659.x.","journal-title":"Br J Haematol"},{"issue":"5","key":"5091_CR38","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s12185-010-0586-9","volume":"91","author":"H Takamatsu","year":"2010","unstructured":"Takamatsu H, Yamashita T, Kotani T, Sawazaki A, Okumura H, Nakao S: Ischemic heart disease associated with bortezomib treatment combined with dexamethasone in a patient with multiple myeloma. Int J Hematol. 2010, 91 (5): 903-906. 10.1007\/s12185-010-0586-9.","journal-title":"Int J Hematol"},{"issue":"3","key":"5091_CR39","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1177\/1078155210367839","volume":"17","author":"CA Dasanu","year":"2011","unstructured":"Dasanu CA: Complete heart block secondary to bortezomib use in multiple myeloma. J Oncol Pharm Pract. 2011, 17 (3): 282-284. 10.1177\/1078155210367839.","journal-title":"J Oncol Pharm Pract"},{"issue":"2","key":"5091_CR40","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bbagrm.2010.09.001","volume":"1809","author":"YF Li","year":"2011","unstructured":"Li YF, Wang X: The role of the proteasome in heart disease. Biochim Biophys Acta. 2011, 1809 (2): 141-149. 10.1016\/j.bbagrm.2010.09.001.","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"5091_CR41","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/cvr\/cvq217","volume":"88","author":"M Tang","year":"2010","unstructured":"Tang M, Li J, Huang W, Su H, Liang Q, Tian Z, Horak KM, Molkentin D, Wang X: Proteasome functional insufficiency activates the calcineurin-NFAT pathway in cardiomyocytes and promotes maladaptive remodelling of stressed mouse hearts. Cardiovasc Res. 2010, 88 (3): 424-433. 10.1093\/cvr\/cvq217.","journal-title":"Cardiovasc Res"},{"issue":"Suppl 1","key":"5091_CR42","first-page":"P228","volume":"98","author":"N Korde","year":"2013","unstructured":"Korde N, Zingone A, Kwok ML, Manasanch EE, Bhutani M, Tageja N, Kazandjian D, Mailankody S, Costello R, Zhang Y, Burton D, Carter G, Wu P, Mulquin M, Zuchlinski D, Maric I, Calvo KR, Braylan RC, Roschewski M, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Kurdziel K, Choyke P, Steinberg SM, Landgren O: Phase 2 clinical and correlative study of carfilzomib, lenalidomide, and dexamethasone followed by lenalidomide extended dosing (CRD-R) in newly diagnosed multiple myeloma (MM) patients. Haematologica. 2013, 98 (Suppl 1): P228-abstr","journal-title":"Haematologica"},{"issue":"Suppl 1","key":"5091_CR43","first-page":"O","volume":"13","author":"O Landgren","year":"2013","unstructured":"Landgren O, Manasanch EE, Kwok M, Flanders A, Zingone A, Costello R, Mulquin M, Zuchlinski D, Carter G, Maric I, Calvo K, Braylan R, Tembhare P, Yuan C, Stetler-Stevenson M, Arthur DC, Lindenberg L, Choyke P, Kurdziel K, Steinberg S, Roschewski M, Korde N: Clinical and correlative (phase II) pilot study \u2013 carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (Dex) in high risk smoldering multiple myeloma (\u201cearly myeloma\u201d). Clin Lymphoma Myeloma Leuk. 2013, 13 (Suppl 1): O-6. abstr","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-915.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-14-915\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-14-915","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T10:53:53Z","timestamp":1598525633000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-14-915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["5091"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-14-915","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12]]},"article-number":"915"}}